DK2301583T3 - Lentivirusvektormedieret genoverførsel og anvendelser deraf - Google Patents

Lentivirusvektormedieret genoverførsel og anvendelser deraf

Info

Publication number
DK2301583T3
DK2301583T3 DK10177185.5T DK10177185T DK2301583T3 DK 2301583 T3 DK2301583 T3 DK 2301583T3 DK 10177185 T DK10177185 T DK 10177185T DK 2301583 T3 DK2301583 T3 DK 2301583T3
Authority
DK
Denmark
Prior art keywords
applications
gene transfer
mediated gene
lentivirus vector
lentivirus
Prior art date
Application number
DK10177185.5T
Other languages
English (en)
Inventor
Timothy J Stout
Binoy Appukuttan
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of DK2301583T3 publication Critical patent/DK2301583T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK10177185.5T 2000-12-19 2001-12-18 Lentivirusvektormedieret genoverførsel og anvendelser deraf DK2301583T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25670100P 2000-12-19 2000-12-19
EP01985065.0A EP1343532B1 (en) 2000-12-19 2001-12-18 Lentiviral vector-mediated gene transfer and uses thereof

Publications (1)

Publication Number Publication Date
DK2301583T3 true DK2301583T3 (da) 2012-12-10

Family

ID=22973247

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10177185.5T DK2301583T3 (da) 2000-12-19 2001-12-18 Lentivirusvektormedieret genoverførsel og anvendelser deraf
DK01985065.0T DK1343532T3 (da) 2000-12-19 2001-12-18 Lentivirusvektormedieret genoverførsel og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK01985065.0T DK1343532T3 (da) 2000-12-19 2001-12-18 Lentivirusvektormedieret genoverførsel og anvendelser deraf

Country Status (15)

Country Link
US (1) US20020114783A1 (da)
EP (2) EP2301583B1 (da)
JP (2) JP4280496B2 (da)
KR (3) KR20030075152A (da)
CN (2) CN101732731B (da)
AU (2) AU3405302A (da)
CA (1) CA2432301C (da)
DK (2) DK2301583T3 (da)
ES (2) ES2393717T3 (da)
IL (2) IL156427A0 (da)
NZ (1) NZ526558A (da)
PT (2) PT2301583E (da)
RU (1) RU2288742C2 (da)
WO (1) WO2002049677A1 (da)
ZA (1) ZA200304664B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122181B2 (en) * 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
PT2301583E (pt) * 2000-12-19 2012-12-06 Res Dev Foundation Transferência de genes mediada por vetor de lentivírus
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
AU2003277910A1 (en) * 2002-09-27 2004-04-19 Novartis Ag Ocular gene therapy
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
CA2536599A1 (en) * 2003-08-29 2005-03-10 Kaneka Corporation Method of constructing transgenic bird using lentivirus vector and transgenic bird obtained thereby
WO2006119128A2 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
WO2008044339A1 (en) * 2006-10-13 2008-04-17 Aqumen Biopharmaceuticals K.K. Therapeutic/preventive agent for intraocular disease containing statin compound
CN101870734B (zh) * 2010-05-25 2012-06-20 北京大学 一种抑制新生血管生成的融合多肽及其编码基因与应用
RU2444734C1 (ru) * 2010-11-03 2012-03-10 ФГУ Ростовский НИИ акушерства и педиатрии Министерства по здравоохранению и социальному развитию РФ Способ прогнозирования невынашивания беременности ранних сроков инфекционного генеза
WO2015130783A1 (en) 2014-02-25 2015-09-03 Research Development Foundation Sty peptides for inhibition of angiogenesis
WO2016073556A1 (en) * 2014-11-09 2016-05-12 The Trustees Of The University Of Pennsylvania Vision test for determining retinal disease progression
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
CN111398595A (zh) * 2020-02-17 2020-07-10 天津医科大学眼科医院 一种血浆小细胞外囊泡中的蛋白质tnfaip8的应用和检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241855A (en) * 1991-03-07 1994-04-27 Gen Hospital Corp Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
US5969120A (en) * 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
WO1997041824A2 (en) * 1996-05-03 1997-11-13 Abbott Laboratories Antiangiogenic peptides derived from plasminogen
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
JPH1180024A (ja) * 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
AU3755900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
PT2301583E (pt) * 2000-12-19 2012-12-06 Res Dev Foundation Transferência de genes mediada por vetor de lentivírus

Also Published As

Publication number Publication date
NZ526558A (en) 2004-06-25
PT2301583E (pt) 2012-12-06
CN1487841A (zh) 2004-04-07
JP2009137998A (ja) 2009-06-25
CA2432301A1 (en) 2002-06-27
EP1343532B1 (en) 2013-04-24
JP2004520307A (ja) 2004-07-08
KR20030075152A (ko) 2003-09-22
KR101026078B1 (ko) 2011-03-31
EP1343532A4 (en) 2006-03-15
IL156427A (en) 2011-06-30
RU2288742C2 (ru) 2006-12-10
CN101732731A (zh) 2010-06-16
CN101732731B (zh) 2013-04-10
ES2393717T3 (es) 2012-12-27
AU3405302A (en) 2002-07-01
JP4280496B2 (ja) 2009-06-17
DK1343532T3 (da) 2013-07-29
EP2301583A1 (en) 2011-03-30
AU2002234053B2 (en) 2004-07-15
EP2301583B1 (en) 2012-08-22
ZA200304664B (en) 2007-02-28
WO2002049677A1 (en) 2002-06-27
EP1343532A1 (en) 2003-09-17
PT1343532E (pt) 2013-07-29
CA2432301C (en) 2013-06-04
US20020114783A1 (en) 2002-08-22
CN100591359C (zh) 2010-02-24
KR20080080684A (ko) 2008-09-04
KR20100011994A (ko) 2010-02-03
ES2422301T3 (es) 2013-09-10
IL156427A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DK2325317T3 (da) Receptornukleinsyrer og polypeptidr
DK1278763T3 (da) 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
DK1341769T3 (da) Bakterielle gyrase-inhibitorer og anvendelser deraf
DK1436309T3 (da) BGL3-beta-glukosidase og nukleinsyrer kodende derfor
IS8358A (is) Truflandi RNA tvíþáttungur með slétta enda og 3'-afbrigði
DK2418220T3 (da) Interferon-alpha-antistoffer og anvendelser deraf
NO20034405L (no) Anti-ostepontin-antistoff og anvendelse derav
DK1122244T3 (da) Uracilforbindelser og anvendelse deraf
NO20024355D0 (no) Nukleosidforbindelser og anvendelser derav
DK1495053T3 (da) Angiopoietin-2 og angiopoietin-1-specifikke bindemidler
EP1412378A4 (en) APTAMERS AND ANTIAPTAMERS
EP1424392A4 (en) NEW SECRETIONAL PROTEINS AND DNA FOR THEM
DE60208264D1 (de) Übertragungsblätter
DK2301583T3 (da) Lentivirusvektormedieret genoverførsel og anvendelser deraf
DK1322597T3 (da) Fremgangsmåde og intermediære
FR2814754B1 (fr) Listeria innocua, genome et applications
NO20022605L (no) Kjemiske fremgangsmåter og mellomprodukter
NO20030882D0 (no) Glasskeramikkmasse og anvendelse derav
AU2002234053A1 (en) Lentiviral vector-mediated gene transfer and uses thereof
NO20025968D0 (no) Pyridin-2-yl-aminoalkylkarbonylglycyl-<beta>-alanin og derivater derav
NO20042693L (no) Kateterpreparat og anvendelser derav
NO20021305L (no) DNA-konstruksjon og dens anvendelse
DK1330525T3 (da) NOD2-nukleinsyrer og proteiner